By: Allison Gatlin
Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock edged lower late, still in a downtrend.
United States (National)
Allison Gatlin
Geo Focus
Coverage Attributes:
Beta
Promotional:
37
%
Informative:
31
%
Data Driven:
15
%
Opinion:
5
%
Reviews:
4
%
Themes Covered:
Not enough data
Pitching Insights
Allison Gatlin's coverage primarily focuses on the healthcare and pharmaceutical industry, with an emphasis on investment analysis and data citations. To effectively reach out to her, consider providing insights related to new drug developments, company financials, or market trends within the healthcare and pharmaceutical sector.
Given Allison's focus on investment analysis and data-driven reporting, she may be receptive to pitches that include statistical evidence or exclusive access to pertinent industry data that supports a particular trend or development in the healthcare and pharmaceutical field.
While Allison does not have a specific geographic focus mentioned, her coverage indicates a global view of the healthcare and pharmaceutical industry. Therefore, pitches should encompass international as well as domestic perspectives when relevant.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
